Two vaccine makers said on Thursday that their booster shots increased significantly increasing antibody levels against omicrons, in an encouraging sign amid increasing Covid infection worldwide because of the spread of a very contagious variant.
The AstraZeneca pharmaceutical company, citing data from the Lab Study of the University of Oxford, said on Thursday that the three doses of the covid vaccine dose were effective against the omicron variant which spread quickly.
The findings of this study have not been published in the medical journals that review peer-reviewed, fits them from rivals Pfizer-Biontech and Modera, who also found the third dose of their shots working against Omicron.
The study of the AstraZeneca vaccine, Vaxzevria, known as a covishield in India, showed that after a three-dose vaccine course, the level of neutralization against Omicron was widely similar to those against the Virus Delta variant after two doses.
The company registered in London said researchers in Oxford who conducted this research were independent of those who worked on vaccines with Astrazeneca.
“Because we better understand Omicron, we believe that we will find that the T-cell response provides a long-lasting protection against disease and severe inpatient care,” said the Head of Biopharmacy Astrazeneca R & D, referring to the important component of the immune system that responded fight infection.
The antibody level against Omicron after a booster shot was higher than antibodies in people who had been infected and recovered naturally from Covid-19, Anglo-Sweden drug makers added.
Even though the initial positive data for the company, AstraZeneca said that it worked with its Oxford’s partner to produce a vaccine adjusted for Omicron, joining a similar effort from other vaccines.
The Oxford study analyzed blood samples from those infected with Covid-19, they were vaccinated with two doses and booster, and those who were previously infected with other variants of concerns.
This includes a sample of 41 people given three vaccine doses.
The previous hour, US drug maker Novavax Inc.
said the initial data showed a two-dose vaccine vaccine, proteinbased – authorized to be used by the EU and who had not been approved by the US – also produced an immune response to Omicron.
Novavax said that accepting additional booster doses of the vaccine increased the immune response to Omicron.
Data was taken from the ongoing Novavax study for the effectiveness of the vaccine in adolescents and as a booster.
“We were encouraged that raising responses to all variants,” said Gregory M.
Glenn, president of the research and development of Novavax.
Novavax still works to develop Omicron special vaccines and say on Wednesdays that are expected to start producing varianspecific shots in January